Company news
OPKO Health, Inc. news in 2021
OPKO Health, Inc.'s news releases, calls and decks from 2021, newest first.
OPKO Health Announces Topline Results from Phase 2 Trial Evaluating RAYALDEE to Treat Symptomatic COVID-19 Outpatients
December 22, 2021
OPKO Health Receives U.S. FDA Approval for the 4Kscore® Test
December 7, 2021
OPKO Health Announces the Passing of Director Dr. Richard Lerner
December 5, 2021
OPKO Health Announces Participation in Piper Sandler 33rd Annual Virtual Healthcare Conference
November 28, 2021
BioReference Laboratories Announces Readiness for COVID-19 Testing if the Omicron COVID-19 Variant Emerges in The U.S.
November 28, 2021
OPKO Health Reports 2021 Third Quarter Business Highlights and Financial Results
October 27, 2021
OPKO Health to Report Third Quarter 2021 Financial Results on October 28, 2021
October 24, 2021
Pfizer and OPKO Announce Extension of U.S. FDA Review of Biologics License Application of Somatrogon for Pediatric Growth Hormone Deficiency
September 23, 2021
LeaderMed Group and OPKO Health Form Joint Venture to Develop and Commercialize Oxyntomodulin and Factor VIIa-CTP in China and Other Asian Territories
September 13, 2021
OPKO Health to Participate in Two Upcoming Investment Conferences
August 29, 2021
OPKO Health Completes Enrollment in Phase 2 Trial Evaluating RAYALDEE as a Treatment for Symptomatic COVID-19 Outpatients
August 29, 2021
BioReference Laboratories Acquires U.S. Ariosa Centralized Laboratory Prenatal Testing Business
August 15, 2021
OPKO Health Reports 2021 Second Quarter Business Highlights and Financial Results
July 28, 2021
OPKO Health to Report Second Quarter 2021 Financial Results on July 29, 2021
July 19, 2021
OPKO Health Licenses Oligonucleotide Therapeutics Platform to CAMP4 Therapeutics
July 11, 2021
OPKO Health to Present at the Ladenburg Thalmann Healthcare Conference
July 7, 2021
OPKO Health Appoints Katherine Stueland as President and CEO of GeneDx
June 21, 2021
BioReference Laboratories Announces First COVID-19 Testing Program for Cruise Industry
June 21, 2021
OPKO Health to Develop and Commercialize RAYALDEE® in Greater China with Nicoya Therapeutics
June 20, 2021
OPKO Health Announces Sale of its Sterile Fill and Finish Manufacturing Facility in Ireland
June 16, 2021
OPKO Health to Participate in the Jefferies Virtual Healthcare Conference
May 26, 2021
OPKO Health Reports Transfer of Licensed Rights to RAYALDEE® in Japan to Vifor
May 23, 2021
OPKO Health Enters into Exchange Agreements with Certain 4.5% Convertible Senior Noteholders
May 6, 2021
OPKO Health Reports 2021 First Quarter Business Highlights and Financial Results
April 27, 2021
Major League Soccer Renews with BioReference Laboratories as COVID-19 Testing Provider for Second Year
April 26, 2021
OPKO Health to Report First Quarter 2021 Financial Results on April 28, 2021
April 21, 2021
BioReference Laboratories Expands Its Major League Sports Relationships with Addition of Major League Baseball
March 31, 2021
BioReference Laboratories Expands COVID-19 School Testing Program
March 25, 2021
EMA Accepts Marketing Application for Somatrogon to Treat Pediatric Patients with Growth Hormone Deficiency
February 25, 2021
New York State Partners with BioReference Laboratories to Spearhead the NY Forward COVID-19 Rapid Test Program to Help Reopen the New York Economy
February 21, 2021
OPKO Health Reports 2020 Fourth Quarter Business Highlights and Financial Results
February 17, 2021
OPKO Health to Report Fourth Quarter 2020 Financial Results on February 18, 2021
February 2, 2021
New Drug Application Submitted to PMDA in Japan for Somatrogon, to Treat Pediatric Patients with Growth Hormone Deficiency
January 27, 2021
OPKO Health's GeneDx Adds Repeat Expansion Analysis Genetic Tests for Diagnosis of Spinocerebellar Ataxia (SCA), Friedreich Ataxia, and Other Common Forms of Hereditary Ataxia
January 25, 2021
OPKO Health's BioReference Laboratories Team-up with the National Basketball Association and National Hockey League to Provide Players and Staff with COVID-19 Testing
January 25, 2021
OPKO Health's BioReference Laboratories Introduces Scarlet Health™, an In-Home Diagnostic Service to Expand Digital Health Access
January 12, 2021
OPKO Health to Present at the 39th Annual J.P. Morgan Healthcare Conference
January 4, 2021
US FDA Accepts Regulatory Submission from Pfizer and OPKO for Review of Somatrogon to Treat Pediatric Patients with Growth Hormone Deficiency
January 3, 2021
OPKO Health's BioReference Laboratories Reports Results of the Largest COVID-19 Public School Testing Program Nationwide
January 3, 2021
Calls in 2021
Decks in 2021
- Investor Presentation (January 2021)
Investor deck · 25 slides · Jan 13, 2021